|
| | Publication Year | Title | Author(s) |
| 1 | 1-Sep-2023 | Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. | Shanmuganathan, Naranie; Wadham, Carol; Shahrin, NurHezrin; Feng, Jinghua; Thomson, Daniel; Wang, Paul; Saunders, Verity; Kok, Chung Hoow; King, Rob M; Kenyon, Rosalie R; Lin, Ming; Pagani, Ilaria S; Ross, David M; Yong, Agnes S M; Grigg, Andrew P ; Mills, Anthony K; Schwarer, Anthony P ; Braley, Jodi; Altamura, Haley; Yeung, David T; Scott, Hamish S; Schreiber, Andreas W; Hughes, Timothy P; Branford, Susan |
| 2 | 26-Apr-2021 | The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia. | Rees, Matthew J ; Wu, Simon; Mokoonlall, Mridula; Dix, Caroline H K; Bryant, Christian E; D'Rozario, James; Schwarer, Anthony P ; Grigg, Andrew P ; Tiong, Ing S |
| 3 | Mar-2021 | Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. | Tiong, Ing S ; Dillon, Richard; Ivey, Adam; Teh, Tse-Chieh; Nguyen, Phillip; Cummings, Nicholas; Taussig, David C; Latif, Annie-Louise; Potter, Nicola E; Runglall, Manohursingh; Russell, Nigel H; Raj, Kavita; Schwarer, Anthony P ; Fong, Chun Yew ; Grigg, Andrew P ; Wei, Andrew H |
| 4 | Jul-2019 | Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response. | Hamadi, Abdullah; Grigg, Andrew P ; Dobie, Gasim; Burbury, Kate L; Schwarer, Anthony P ; Kwa, Faith A; Jackson, Denise E |
| 5 | 2018 | Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. | Ross, David M; Pagani, Ilaria S; Shanmuganathan, Naranie; Kok, Chung H; Seymour, John F; Mills, Anthony K; Filshie, Robin J; Arthur, Christopher K; Dang, Phuong; Saunders, Verity A; Braley, Jodi; Yong, Agnes S; Yeung, David T; White, Deborah L; Grigg, Andrew P ; Schwarer, Anthony P ; Branford, Susan; Hughes, Timothy P |
| 6 | 23-May-2017 | The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. | Fox, Lucy C; Cummins, Katherine D; Costello, Ben; Yeung, David; Cleary, Rebecca; Forsyth, Cecily; Tatarczuch, Maciek; Burbury, Kate; Motorna, Olga; Shortt, Jake; Fleming, Shaun; McQuillan, Andrew; Schwarer, Anthony P ; Harrup, Rosemary; Holmes, Amy; Ratnasingam, Sumita; Chan, Kah-Lok; Hsu, Wei-Hsun; Ashraf, Asma; Putt, Faye; Grigg, Andrew P |
| 7 | Apr-2016 | Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era | Jalali, Azim; Ha, Francis J; Chong, Geoff; Grigg, Andrew P ; Mckendrick, Joe; Schwarer, Anthony P ; Doig, Rowan; Hamid, Anis; Hawkes, Eliza A |
| 8 | 17-Dec-2014 | TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. | Yeung, David T; Osborn, Michael P; White, Deborah L; Branford, Susan; Braley, Jodi A; Herschtal, Alan; Kornhauser, Michael; Issa, Samar; Hiwase, Devendra K; Hertzberg, Mark; Schwarer, Anthony P ; Filshie, Robin; Arthur, Christopher K; Kwan, Yiu Lam; Trotman, Judith; Forsyth, Cecily J; Taper, John; Ross, David M; Beresford, Jennifer; Tam, Constantine; Mills, Anthony K; Grigg, Andrew P ; Hughes, Timothy P |
Loading...
2
0
20
0
false